What is Spyre Therapeutics, Inc.'s stock issuance proceeds?

Spyre Therapeutics, Inc. (SYRE) reported stock issuance proceeds of $2.68M in Q1 2026.

How has Spyre Therapeutics, Inc.'s stock issuance proceeds changed year-over-year?

Spyre Therapeutics, Inc.'s stock issuance proceeds increased by 1127.5% year-over-year, from $218K to $2.68M.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Spyre Therapeutics, Inc. SYRE Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Merck & Co.MRK

$157M+726%

TG TherapeuticsTGTX

$763K+3,533%

BridgeBio PharmaBBIO

$22.59M—

Summit TherapeuticsSMMT

$3.8M+88.1%

Protagonist TherapeuticsPTGX

——

Kymera TherapeuticsKYMR

——

Other financials

Income statement

See full

Revenue-—

Operating income-$45.6M+14.8%

Net income-$69.0M-54.1%

EPS (diluted)-$0.74-23.3%

Balance sheet

See full

Cash & equivalents$97.2M+100%

Total debt$4.3M-9.6%

Total equity$670.8M+39.0%

Total assets$764.0M+34.1%

Cash flow

See full

Operating cash flow-$57.4M-40.0%

CapEx-—

Free cash flow-$39.4M-26.8%

Valuation

See full

Market cap$7.67B+307%

Profitability

See full

Operating margin-39,428.9%-49,795pp

Net margin-52,939.7%-61,871pp

FCF margin-3,442.8%-3,807pp

Returns & leverage

See full

Return on equity-31.1%-10.7pp

Debt / equity0.1×+0.1×

Current ratio9×+0.9×

Where this comes from

Reported directly by Spyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.

The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Spyre Therapeutics, Inc.'s stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Spyre Therapeutics, Inc.'s stock issuance proceeds?: Spyre Therapeutics, Inc. (SYRE) reported stock issuance proceeds of $2.68M in Q1 2026.
How has Spyre Therapeutics, Inc.'s stock issuance proceeds changed year-over-year?: Spyre Therapeutics, Inc.'s stock issuance proceeds increased by 1127.5% year-over-year, from $218K to $2.68M.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.